Lombard Medical Technologies PLC Live case demonstration using Aorfix at LINC 2014

TIDMLMT

Lombard Medical Technologies PLC

30 January 2014

Lombard Medical Technologies PLC

("Lombard Medical" or "the Company")

Live case demonstration using Aorfix(TM) at LINC 2014

London, UK and Irvine, CA, 30 January, 2014 - Lombard Medical Technologies PLC (AIM: LMT), the specialist medical device company focused on Endovascular Aortic Repair ("EVAR") of abdominal aortic aneurysms ("AAAs"), announces that yesterday a team of surgeons, led by Dr. Andrej Schmidt, Oberarzt (Senior Physician) Angiologie, Leipzig Park-Krankenhaus, successfully performed a live case demonstration of a challenging AAA repair using Aorfix(TM), the Company's flexible endovascular stent graft, to over 500 physicians at the 2014 Leipzig Interventional Course (LINC), Leipziger Messe, Leipzig, Germany.

Prior to the live case Dr Schmidt demonstrated the Company's new simulation technology, developed in conjunction with Simbionix USA Corporation, which uses a patient CT scan to allow physicians to practice the procedure on a simulation of that patient's particular AAA anatomy ahead of the actual surgery.

During the procedure, which was broadcast live from Park Hospital Leipzig, a panel of prominent vascular surgeons, interventional radiologists and interventional cardiologists, chaired by Professor Vicente Riambau, Professor and Chief of Vascular Surgery, Hospital Clinic of Barcelona, gave a series of presentations discussing their experiences of Aorfix in complex AAA anatomy.

Aorfix is the only AAA stent graft approved in Europe and the US, for the treatment of patients with neck angulations up to and including 90 degrees.

Simon Hubbert, CEO of Lombard Medical Technologies, commented:

"LINC is a very high profile event for international physicians and provides the ideal platform to demonstrate the advantages of Aorfix in the treatment of challenging AAA anatomy. We are also delighted to have the opportunity to showcase our new simulation technology, which we believe will significantly enhance the training experience for physicians using Aorfix.

Professor Vicente Riambau commented:

"Aorfix provides physicians with a minimally invasive treatment option for patients with tortuous AAA anatomies who would otherwise require open surgery, which is more invasive and typically carries higher associated risks."

-Ends-

For further information:

 
 Lombard Medical Technologies PLC           Tel: +44(0)1235 750 800 
 Simon Hubbert, Chief Executive Officer 
  Ian Ardill, Chief Financial Officer 
 
 Canaccord Genuity Limited                  Tel: +44(0)20 7523 8000 
  Lucy Tilley / Tim Redfern / Henry 
  Fitzgerald O'Connor / Dr Julian Feneley 
 
 FTI Consulting                             Tel: +44(0)20 7831 3113 
  Simon Conway / Stephanie Cuthbert 
  / Victoria Foster Mitchell 
 
 Allen & Caron                                Tel: +1 (949) 474 4300 
  Matt Clawson

About Leipzig Interventional Course

The Leipzig Interventional Course is committed to advancing the scientific and clinical evaluation and treatment of patients with complex vascular disease through an interdisciplinary discussion of novel endovascular techniques. LINC is a comprehensive and international live course designed to foster collaboration between physicians of differing specialities and to promote the understanding and development of endovascular therapies that can be incorporated into daily clinical practice. The involvement of leading interventional centers from Europe, North, and South America as live transmission sites, as well as the presence of interventional experts provides a broad coverage of different interventional approaches and techniques. Further information can be found at www.leipzig-interventional-course.com

About Abdominal Aortic Aneurysms

AAAs are a balloon-like enlargement of the aorta which, if left untreated, may rupture and cause death. Approximately 4.5 million people are living with AAAs in the developed world and each year 600,000 new cases are diagnosed.

In the U.S. aortic aneurysm disease is among the leading cause of death and it is estimated that 1.7 million people over the age of 55 have abdominal aortic aneurysms.

About Lombard Medical

Lombard Medical Technologies PLC (AIM: LMT) is a medical device company focused on device solutions for the abdominal aortic aneurysm (AAA) repair market. The Company's lead product, Aorfix, is an endovascular stent graft which has been specifically designed to solve the problems that exist in treating complex tortuous anatomy, which is often present in advanced AAA disease. Aorfix is the only stent graft approved for AAA neck angulations of up to 90 degrees and is currently being commercialized worldwide. Aorfix is the first AAA stent graft not of U.S. origin to gain FDA approval. The Company is headquartered in Oxfordshire, England with U.S. operations in Irvine, CA.

Further background on the Company can be found at www.lombardmedical.com.

FORWARD-LOOKING STATEMENTS

This announcement may contain forward-looking statements that reflect the Company's current expectations regarding future events, including the commercialization and regulatory clearance of the Company's products, the Group's liquidity and results of operations, as well as the Group's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the success of the Company's research and development and commercialization strategies, the uncertainties related to the regulatory process and the acceptance of the Company's products by hospitals and other medical professionals.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAEAXFEDAPLEEF

Lombard Medical Technologies (LSE:LMT)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024